Xilio Therapeutics, Inc. (NASDAQ:XLO) Short Interest Down 17.1% in March

Xilio Therapeutics, Inc. (NASDAQ:XLO) saw a significant decrease in short interest during the month of March. As of March 15th, there was short interest totalling 575,500 shares, a decrease of 17.1% from the February 28th total of 694,600 shares. Approximately 3.5% of the shares of the stock are short sold. Based on an average daily volume of 3,880,000 shares, the short-interest ratio is presently 0.1 days.

Hedge Funds Weigh In On Xilio Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of XLO. Trustees of Columbia University in the City of New York purchased a new position in shares of Xilio Therapeutics during the 4th quarter valued at about $238,000. Balyasny Asset Management L.P. raised its stake in shares of Xilio Therapeutics by 26.0% during the fourth quarter. Balyasny Asset Management L.P. now owns 343,230 shares of the company’s stock worth $328,000 after acquiring an additional 70,744 shares in the last quarter. Aptus Capital Advisors LLC bought a new stake in shares of Xilio Therapeutics in the 4th quarter worth approximately $39,000. Gilead Sciences Inc. purchased a new stake in shares of Xilio Therapeutics in the 4th quarter valued at $8,696,000. Finally, Raymond James Financial Inc. bought a new position in shares of Xilio Therapeutics during the 4th quarter valued at $48,000. 54.29% of the stock is currently owned by hedge funds and other institutional investors.

Xilio Therapeutics Price Performance

Shares of Xilio Therapeutics stock opened at $0.68 on Wednesday. Xilio Therapeutics has a 1 year low of $0.63 and a 1 year high of $1.70. The firm has a market cap of $35.26 million, a PE ratio of -0.40 and a beta of -0.38. The company has a 50 day simple moving average of $0.85 and a two-hundred day simple moving average of $0.93.

Xilio Therapeutics (NASDAQ:XLO) last posted its quarterly earnings data on Tuesday, March 11th. The company reported ($0.20) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.22) by $0.02. The company had revenue of $1.72 million for the quarter, compared to the consensus estimate of $2.26 million. As a group, research analysts anticipate that Xilio Therapeutics will post -1.14 earnings per share for the current year.

About Xilio Therapeutics

Xilio Therapeutics, Inc, a clinical-stage biotechnology company, engages in the discovery and development of tumor-activated immuno-oncology therapies. The company’s checkpoint inhibitor program includes XTX101, an investigational Fc-enhanced, tumor-activated anti-CTLA-4 mAb that is in Phase 2 clinical trial for patients with advanced solid tumors.